{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:02:57Z","timestamp":1789614177130,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10157-026-02930-w","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:16:24Z","timestamp":1785842184000},"page":"1392-1397","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Eldecalcitol in older adults with kidney vulnerability: a narrative review of risk-based use, dose adjustment, and monitoring"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6851-1542","authenticated-orcid":false,"given":"Yoshitaka","family":"Furuto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Namikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Shibuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"2930_CR1","unstructured":"Pharmaceuticals and Medical Devices Agency. Edirol tablets 0.5 \u03bcg and 0.75 \u03bcg (eldecalcitol): package insert. Revised February 2024. Available at: https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/450045_3112006F1023_1_03. Accessed 2 July 2026."},{"issue":"4","key":"2930_CR2","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1007\/s00774-016-0779-2","volume":"35","author":"H Saito","year":"2017","unstructured":"Saito H, Kakihata H, Nishida Y, et al. The safety and effectiveness profile of eldecalcitol in a prospective, post-marketing observational study in Japanese patients with osteoporosis: interim report. J Bone Miner Metab. 2017;35(4):456\u201363. https:\/\/doi.org\/10.1007\/s00774-016-0779-2.","journal-title":"J Bone Miner Metab"},{"issue":"6","key":"2930_CR3","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1007\/s00774-023-01470-7","volume":"41","author":"K Ri","year":"2023","unstructured":"Ri K, Fukasawa T, Masuda S, Tanaka S, Takeuchi M, Yoshida S, et al. Frequency and determinants of serum calcium monitoring during eldecalcitol therapy in patients with osteoporosis. J Bone Miner Metab. 2023;41(6):890\u2013900. https:\/\/doi.org\/10.1007\/s00774-023-01470-7.","journal-title":"J Bone Miner Metab"},{"issue":"2","key":"2930_CR4","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00774-021-01276-5","volume":"40","author":"Y Takeuchi","year":"2022","unstructured":"Takeuchi Y, Saito H, Makishima M, et al. Long-term safety of eldecalcitol in Japanese patients with osteoporosis: a retrospective, large-scale database study. J Bone Miner Metab. 2022;40(2):275\u201391. https:\/\/doi.org\/10.1007\/s00774-021-01276-5.","journal-title":"J Bone Miner Metab"},{"issue":"4","key":"2930_CR5","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.bone.2011.07.011","volume":"49","author":"T Matsumoto","year":"2011","unstructured":"Matsumoto T, Ito M, Hayashi Y, et al. A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures: a randomized, active comparator, double-blind study. Bone. 2011;49(4):605\u201312. https:\/\/doi.org\/10.1016\/j.bone.2011.07.011.","journal-title":"Bone"},{"key":"2930_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.854439","volume":"13","author":"H Liu","year":"2022","unstructured":"Liu H, Wang G, Wu T, Mu Y, Gu W. Efficacy and safety of eldecalcitol for osteoporosis: a meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2022;13:854439. https:\/\/doi.org\/10.3389\/fendo.2022.854439.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2930_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-022-01071-3","volume":"17","author":"L Cui","year":"2022","unstructured":"Cui L, Xia W, Yu C, Dong S, Pei Y. Overview of the clinical efficacy and safety of eldecalcitol for the treatment of osteoporosis. Arch Osteoporos. 2022;17(1):74. https:\/\/doi.org\/10.1007\/s11657-022-01071-3.","journal-title":"Arch Osteoporos"},{"key":"2930_CR8","unstructured":"Pharmaceuticals and Medical Devices Agency. Review report: Edirol capsules 0.5 \u03bcg and 0.75 \u03bcg (eldecalcitol). 2010. Available at: https:\/\/www.pmda.go.jp\/drugs\/2011\/P201100025\/450045000_22300AMX00416_A100_1.pdf. Accessed 2 July 2026."},{"issue":"1","key":"2930_CR9","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1080\/0886022X.2019.1578667","volume":"41","author":"S Aihara","year":"2019","unstructured":"Aihara S, Yamada S, Oka H, et al. Hypercalcemia and acute kidney injury induced by eldecalcitol in patients with osteoporosis: a case series of 32 patients at a single facility. Ren Fail. 2019;41(1):88\u201397. https:\/\/doi.org\/10.1080\/0886022X.2019.1578667.","journal-title":"Ren Fail"},{"key":"2930_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-72505-w","volume":"14","author":"Y Kawai","year":"2024","unstructured":"Kawai Y, Uneda K, Miyata S, et al. A pharmacovigilance study on clinical factors of active vitamin D3 analog-related acute kidney injury using the Japanese Adverse Drug Event Report Database. Sci Rep. 2024;14:21356. https:\/\/doi.org\/10.1038\/s41598-024-72505-w.","journal-title":"Sci Rep"},{"issue":"16","key":"2930_CR11","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1001\/jama.2022.18331","volume":"328","author":"MD Walker","year":"2022","unstructured":"Walker MD. Hypercalcemia: a review. JAMA. 2022;328(16):1624\u201336. https:\/\/doi.org\/10.1001\/jama.2022.18331.","journal-title":"JAMA"},{"issue":"4 Suppl","key":"2930_CR12","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4 Suppl):S117\u2013314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018.","journal-title":"Kidney Int"},{"issue":"1","key":"2930_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","volume":"7","author":"KDIGO CKD-MBD Update Work Group","year":"2017","unstructured":"KDIGO CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl (2011). 2017;7(1):1\u201359. https:\/\/doi.org\/10.1016\/j.kisu.2017.04.001.","journal-title":"Kidney Int Suppl (2011)"},{"issue":"1","key":"2930_CR14","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1093\/ndt\/gfaa192","volume":"36","author":"P Evenepoel","year":"2021","unstructured":"Evenepoel P, Cunningham J, Ferrari S, et al. European consensus statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4-G5D. Nephrol Dial Transplant. 2021;36(1):42\u201359. https:\/\/doi.org\/10.1093\/ndt\/gfaa192.","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"2930_CR15","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1248\/yakushi.25-00104","volume":"146","author":"S Oda","year":"2026","unstructured":"Oda S, Miyoshi T, Furuta K, Takechi K, Otsuka T. Relationship between hypercalcemia and renal function with eldecalcitol. Yakugaku Zasshi. 2026;146(3):253\u20138. https:\/\/doi.org\/10.1248\/yakushi.25-00104.","journal-title":"Yakugaku Zasshi"},{"issue":"1-2","key":"2930_CR16","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jsbmb.2010.03.035","volume":"121","author":"T Matsumoto","year":"2010","unstructured":"Matsumoto T, Takano T, Yamakido S, et al. Comparison of the effects of eldecalcitol and alfacalcidol on bone and calcium metabolism. J Steroid Biochem Mol Biol. 2010;121(1\u20132):261\u20134. https:\/\/doi.org\/10.1016\/j.jsbmb.2010.03.035.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"4","key":"2930_CR17","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1248\/yakushi.24-00160","volume":"145","author":"H Nagae","year":"2025","unstructured":"Nagae H, Nagai-Nakamura H, Noda K, Hagiwara D, Kaneshige S, Kamimura H. Changes in the serum calcium level and renal function after switching from alfacalcidol to eldecalcitol. Yakugaku Zasshi. 2025;145(4):351\u20137. https:\/\/doi.org\/10.1248\/yakushi.24-00160.","journal-title":"Yakugaku Zasshi"},{"key":"2930_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-026-01735-x","author":"Y Jiang","year":"2026","unstructured":"Jiang Y, Zeng Y, Xin L, et al. Eldecalcitol and calcium supplementation in Chinese women with postmenopausal osteoporosis: a prospective observational cohort study. J Bone Miner Metab. 2026. https:\/\/doi.org\/10.1007\/s00774-026-01735-x.","journal-title":"J Bone Miner Metab"},{"key":"2930_CR19","doi-asserted-by":"publisher","DOI":"10.1177\/20543581241283523","volume":"11","author":"R Whitlock","year":"2024","unstructured":"Whitlock R, MacDonald K, Tangri N, Walsh M, Collister D. The efficacy and safety of bisphosphonate therapy for osteopenia\/osteoporosis in patients with chronic kidney disease: a systematic review and individual patient-level meta-analysis of placebo-controlled randomized trials. Can J Kidney Health Dis. 2024;11:20543581241283523. https:\/\/doi.org\/10.1177\/20543581241283523.","journal-title":"Can J Kidney Health Dis"},{"issue":"1","key":"2930_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-025-00919-0","volume":"23","author":"MR Laurent","year":"2025","unstructured":"Laurent MR, Dupont J, Lemahieu W, Dejaeger M, Gielen E, Evenepoel P. Treatment of osteoporosis in patients with chronic kidney disease. Curr Osteoporos Rep. 2025;23(1):26. https:\/\/doi.org\/10.1007\/s11914-025-00919-0.","journal-title":"Curr Osteoporos Rep"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-026-02930-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-026-02930-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-026-02930-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:51:30Z","timestamp":1789613490000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-026-02930-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2930"],"URL":"https:\/\/doi.org\/10.1007\/s10157-026-02930-w","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"assertion":[{"value":"19 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this manuscript, the authors used a large language model to assist with language refinement. The authors reviewed and edited the output critically and take full responsibility for the content of the manuscript.","order":4,"name":"Ethics","label":"Use of AI tools","group":{"name":"EthicsHeading","label":"Declarations"}}]}}